Table 1 Univariate analysis of overall survival
Factors | No. | MST | 95% CI | p value |
|---|---|---|---|---|
Age, y | ||||
> 66 | 109 | 21.5 | 15.3–32.6 | 0.76 |
≤ 66 | 128 | 21.6 | 14.6–29.1 | |
Serum SCC antibody | ||||
> 2 ng/mL | 65 | 23.0 | 10.0–29.0 | 0.42 |
≤ 2 ng/mL | 172 | 21.6 | 18.0–30.6 | |
Combined CTX | ||||
Without | 38 | 10.8 | 6.3–21.5 | 0.000055 |
With | 199 | 26.0 | 18.5–32.8 | |
DFI | ||||
≤ 12 mo | 119 | 14.5 | 12.8–18.8 | 0.0013 |
> 12 months | 118 | 30.6 | 23.2–42.0 | |
DFI | ||||
≤ 24 months | 183 | 18.0 | 14.2–23.2 | 0.0041 |
> 24 months | 54 | 41.0 | 26.0–116.0 | |
KPS | ||||
< 90% | 83 | 14.6 | 12.3–28.0 | 0.11 |
≥ 90% | 154 | 26.0 | 18.0–32.8 | |
No. of LN metastasis | ||||
Mono | 165 | 26.0 | 17.8–33.0 | 0.44 |
Multiple | 72 | 18.8 | 14.6–28.5 | |
LN max diameter | ||||
> 22 mm | 109 | 15.7 | 13.5–23.5 | 0.0052 |
≤ 22 mm | 128 | 29.1 | 19.8–41.1 | |
LN location | ||||
Distant | 90 | 20.2 | 14.2–27.0 | 0.41 |
Locoregional | 147 | 26.4 | 18.0–34.3 | |
Histopathology | ||||
SCC | 231 | 23.0 | 18.0–28.5 | 0.55 |
Others | 6 | 15.0 | 12.0-NA | |